Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS -NO W Oliver Tobin and Brian G Weinshenker
As we approach the 25th anniversary of the introduction of interferon beta-1b, the first disease-modifying therapy (DMT) for multiple sclerosis (MS), consensus has emerged that MS disease-modifying treatments are safe and favorably alter not only short-term but also long-term outcomes, 1-3 although not every study has reached this conclusion. 4 However, no consensus has been reached as to whether or when DMTs can be safely discontinued. Given that DMT for MS accounts for ~75% of the cost of care for a patient with MS who is on a DMT, an era of rapidly rising healthcare inflation makes addressing the issue of DMT discontinuation urgent.
It has been well documented that the frequency of attacks and magnetic resonance imaging (MRI)detected inflammatory disease activity declines with time when considering MS patients as a group. Accordingly, there is good reason to believe that DMT withdrawal might be possible for patients meeting certain criteria (e.g. a disease of long duration, the onset of secondary progressive MS (SPMS), lack of recent relapses, and lack of recent MRI activity). 5 However, disease heterogeneity precludes the confident determination of safety of medication withdrawal for individual patients. There are no prospective trials of discontinuation of DMT in MS, although one is in progress (NCT03073603).
Several studies have shown that patients with SPMS do not benefit from DMT. 6 Therefore, DMT withdrawal might be reasonably considered when SPMS supervenes in a patient with relapsing-remitting MS (RRMS). However, recent clinical trials of two potent DMTs, ocrelizumab in primary progressive MS (PPMS) 7 and siponimod in SPMS, 8 demonstrated slowed progression of disability, even in patients lacking MRI criteria for ongoing inflammatory disease activity. This suggests that even brain MRI detection of subclinical inflammatory activity fails to sensitively identify those who may benefit from a potent DMT. Cohort observational data support benefit of DMT early in the transition period from RRMS to SPMS, although only in patients with ongoing relapses during progression. 9 The definition of "stable" relapsing-remitting MS deserves some consideration. The AFFIRM, SENTINEL, and GLANCE studies of natalizumab and their subsequent open-label extensions with voluntary drug withdrawal in 2005 demonstrated a socalled "rebound" phenomenon of return of disease activity in previously stable patients. 10 A more recent trial of natalizumab discontinuation after 5 years of disease stability demonstrated that over half of patients had recurrent relapsing disease. Therefore, not only is the duration of disease stability important but also, possibly, the specific DMT that has been withdrawn. Patients who required a potent DMT to induce clinical and MRI disease remission are reasonably considered to be at a higher risk of recurrent disease activity when the drug is withdrawn. The age of the patient at drug withdrawal also appears important, at least on a population basis, with patients who discontinue DMT in their 50s being more likely to have subsequent disease activity than patients who discontinue DMT in their 60s. 11 Although the rate of incident MS declines in the sixth decade, new-onset relapsing-remitting MS can occur at any age. 12 Few would argue with implementation of DMT in patients with new-onset relapsing-remitting MS in their 60s, whose prognosis is worse than their younger counterparts.
Some would argue that stability on DMT is equivalent to the previous concept of "benign MS" 13 and that patients who are entirely stable on DMT were patients "destined" to do well, as did 30% of patients prior to the era of DMT. However, patients with long-standing, clinically stable relapsing-remitting MS should not be considered to be identical to patients with benign MS; the former may require DMT to maintain remission. The situation could change radically when DMTs are discontinued in such patients.
In summary, it is likely that some patients with stable relapsing-remitting MS do not require ongoing DMT. However, current data are inadequate to identify such patients prospectively. If a provider or patient is considering discontinuation of DMT, an unbiased discussion of the limitations of the available data is necessary to allow the patient to make an informed decision. Particular caution should be entertained when stopping DMT after a relatively short period of time, when stopping a highly potent DMT, or stopping when there is ongoing MRI-detected disease activity despite clinical stability. Subsequent clinical and radiological monitoring of patients is recommended and the duration of follow-up required is uncertain.
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The author(s) received no financial support for the research, authorship, and/or publication of this article. But this is not the same as stopping a DMT in a patient who is clinically quiescent for several or many years. Both papers describe the small number of case reports and natural history studies which clearly demonstrate treatment interruption in young MS patients with substantial pretreatment relapse and/or MRI activity is a very bad idea. They also correctly point out that clinical equipoise remains, however, for the more challenging question of deliberate DMT discontinuation due to perceived lack of need in aging, clinically and radiographically inactive (no new relapses or brain MRI lesions) MS patients.
This dearth of information has been addressed in a small number of recent papers, 6-10 all of which suffer methodological limitations, some more significant than others. The mean age of discontinuation is between 38 and 50 years in all but one 8 study, so the patients are relatively young. Only two 6,8 report results exclusively with patients who deliberately stopped DMT due to clinical inactivity (one 9 included some who did). In the others, patients stopped for many different reasons (intolerance, pregnancy, insurance interruption, etc.). Only two 6,8 are prospective. MRI data are missing from many of the patients, or not obtained. 10 One is propensity-matched, 10 one 6 has a poorly matched comparator group, and three have no control group. None are blinded as to outcome measures, nor do any have true pretreatment data that would ascertain those with more or less active disease prior to starting a DMT. All, however, have come to the same general conclusion that older patients with absent clinical and MRI activity for extended periods of time while taking a DMT have modest, but some, risk of recurrence or worsening after DMT discontinuation. Concerns have been raised in both arguments, 1,2 and in one 6 of the recent papers addressing this issue, that discontinuation of more highly effective medications, especially natalizumab, may be associated with enhanced risk of recurrence. This worry, however, does not adequately take into account the severity of disease activity prior to starting more highly effective therapy. Until more highly effective therapies are used Visit SAGE journals online journals.sagepub.com/ home/msj SAGE journals
